Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma

Blood

Volumn 94, Issue 10, 1999, Pages 3325-3333

  Freedman, Arnold S ^a   Neuberg, Donna ^b   Mauch, Peter ^b   Soiffer, Robert J ^b   Anderson, Kenneth C ^b   Fisher, David C ^b   Schlossman, Robert ^b   Alyea, Edwin P ^b   Takvorian, Tak ^b   Jallow, Haddy ^b   Kuhlman, Caroline ^b   Ritz, Jerome ^b   Nadler, Lee M ^b   Gribben, John G ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD SAMPLING; BONE MARROW PURGING; CANCER SURVIVAL; DRUG EFFECT; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE;

EID: 0033570991     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.10.3325.422k13_3325_3333     Document Type: Article

References (60)

1. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphoma. N Engl J Med 311: 1471, 1984
2. Gallagher C, Gregory W, Jones A, Stansfeld A, Richards M, Dhaliwal H, Malpas J, Lister T: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470, 1986
3. Dana B, Dahlberg S, Nathwani B, Chase E, Coltman C, Miller T, Fisher R: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644, 1993
4. Johnson P, Rohatiner A, Whelan J, Price C, Love S, Lim J, Mattews J, Norton A, Amess J, Lister T: Patterns of survival in patients with recurrent follicular lymphoma: A 20 year study from a single center. J Clin Oncol 13:140, 1995
5. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J, Harousseau J, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540, 1995
6. Van Besien K, Mehra R, Giralt S, Kantarjian H, Pugh W, Khouri I, Moon Y, Williams P, Andersson B, Przepiorka D, McCarthy P, Gajewski J, Deisseroth A, Cabanillas F, Champlin R: Allogeneic bone marrow transplantation for poor prognosis lymphoma: Response, toxicity, and survival depend on disease histology. Am J Med 100:299, 1996
7. Verdonck L, Dekker A, Lokhorst H, Petersen E, Nieuwenhuis H: Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma. Blood 90: 4201, 1997
8. Schouten HC, Bierman PJ, Vaughan WP, Kessinger A, Vose JM, Weisenburger DD, Armitage JO: Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 74:2579, 1989
9. Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Mauch P, Takvorian T, Soiffer R, Blake K, Yeap B, Coral F, Helfin L, Nadler LM: Autologous bone marrow transplantation in 69 patients with a history of low grade B cell non-Hodgkin's lymphoma. Blood 77:2524, 1991
10. Colombat P, Donadio D, Fouillard L, Milpied N, Tilly H, Pico J, Abrgrall J, Coiffier B, Herbrecht R, Philip T: Value of autologous bone marrow transplantation in follicular lymphoma: A France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 13:157, 1994
11. Rohatiner A, Johnson P, Price C, Arnott, SJ, Amess J, Norton A, Dorey E, Adams K, Whelan J, Matthews J, MacCallum P, Oza A, Lister T: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177, 1994
12. Freedman A, Gribben J, Neuberg D, Mauch P, Soiffer R, Anderson K, Pandite L, Robertson M, Kroon M, Ritz J, Nadler L: High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780, 1996
13. Bierman P, Vose J, Anderson J, Bishop M, Kessinger A, Armitage J: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445, 1997
14. Freedman A, Neuberg D, Mauch P, Gribben J, Soiffer R, Anderson K, Robertson M, Fisher D, Schlossman R, Kroon M, Rhuda C, Kuhlman C, Ritz J, Nadler L: Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 90:4996, 1997
15. Fouillard L, Laporte J, Labopin M, Lesage S, Isnard F, Douay L, Lopez M, Aoudjhane M, Zunic P, Cheron N, Stachowiak J, Lemonnier M, Andreu G, Belkacemi Y, Noel-Walter M, Morel P, Fenaux P, Jouet J, Bauters F, Najman A, Gorin N: Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy posttransplantation - Results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 16:2803, 1998
16. Gribben J, Neuberg D, Barber M, Moore J, Pesek K, Freedman A, Nadler L: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800, 1994
17. Gribben J, Freedman A, Neuberg D, Roy D, Blake K, Woo S, Grossbard M, Rabinowe S, Coral F, Freeman G, Ritz J, Nadler L: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525, 1991
18. Gribben J, Saporito L, Barber M, Blake K, Edwards R, Griffin J, Freedman A, Nadler L: Bone marrow of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion. Blood 80:1083, 1992
19. Gribben J, Neuberg D, Freedman A, Gimmi C, Pesek K, Barber M, Saporito L, Woo S, Coral F, Spector N, Rabinowe S, Grossbard M, Ritz J, Nadler L: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449, 1993
20. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Classification Project. Cancer 49:2112, 1982
21. Harris N, Jaffe E, Stein H, Banks P, Chan J, Cleary M, Delsol G, de Wolf-Peeters C, Falini B, Gatter K, Grogan T, Isaacson P, Knowles D, Mason D, Muller-Hermelink H, Pileri S, Pins M, Ralfkiaer E, Warnke R: Perspective: A revised European American classification of lymphoid neoplasm: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
22. Freedman AS, Takvorian T, Anderson KC, Mauch P, Rabinowe SN, Blake K, Yeap B, Soiffer R, Coral F, Heflin L, Ritz J, Nadler LM: Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 8:1, 1990
23. Gribben JG, Freedman AS, Woo SD, Blake K, Shu RS, Freedman G, Longtine JA, Pinkus GS, Nadler LM: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275, 1991
24. Kaplan E, Maier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
25. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
26. Haas R, Moos M, Mohle R, Dohner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 17:149, 1996
27. Tarella C, Corradini P, Caracciolo D, Astolfi M, Castellino C, Gavarotti P: High dose chemotherapy as upfront treatment in 35 patients with indolent lymphoma induces a high rate of durable clinical and molecular remission. Blood 88:121, 1996
28. Klingemann H, Grigg A, Wilkie-Boyd K, Barnett M, Eaves A, Reece D, Shepard J, Phillips G: Treatment with recombinant interferon (α-2β) early after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306, 1991
29. Vey N, Blaise D, Tiberghein P, Attal M, Pico J, Reiffers J, Harrousseau J, Fiere D, Tabilio A, Gabus R, Brandely M, Maraninchi D: A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. Leuk Lymphoma 21:107, 1996
30. Schultze J, Cardoso A, Freeman G, Seamon M, Daley J, Pinkus G, Gribben J, Nadler L: Follicular lymphomas can be induced to present alloantigen efficiently: A conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 92:8200, 1995
31. Kwak L, Campbell M, Czerwinski D, Hart S, Miller R, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
32. Hsu F, Benike C, Fagnoni F, Liles T, Czerwinski D, Taidi B, Engleman E, Levy R: Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nat Med 2:52, 1996
33. Bendandi M, Gocke C, Kobrin C, Benko F, Sternas L, Watson T, Reynolds C, Kwak L: Molecular complete remissions induced by patient-specific vaccination in most patients with follicular lymphoma. Blood 92:153, 1998
34. Pedrazzini A, Freedman A, Andersen J, Heflin L, Anderson K, Takvorian T, Canellos G, Whitman J, Coral F, Ritz J, Nadler L: Anti-B cell monoclonal antibody purged autologous bone marrow transplantation for B cell non-Hodgkin's lymphoma: Phenotypic reconstitution and B cell function. Blood 74:2203, 1989
35. Multani P, Grossbard M: Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 16:3691, 1998
36. Grossbard M, Niedzwiecki D, Nadler L: Anti-B4-blocked ricin (anti-B4-bR) adjuvant therapy post-autologus bone marrow transplant (ABMT)(CALGB 9254): A phase III Intergroup study. Proc Am Soc Clin Oncol 17:A8, 1998
37. Shan D, Ledbetter J, Press O: Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91:1644, 1998
38. Witherspoon R, Fisher L, Schoch G, Martin P, Sullivan K, Sanders J, Deeg H, Doney K, Thomas D, Storb R: Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 321:784, 1989
39. Lowsky R, Lipton J, Fyles G, Minden M, Meharchand J, Tejpar I, Atkins H, Sutcliffe S, Messner H: Secondary malignancies after bone marrow transplantation in adults. J Clin Oncol 12:2187, 1994
40. Stone R, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S, Aster J, Leavitt P, Mauch P, Freedman A, Nadler L: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535, 1994
41. Miller J, Arthur D, Litz C, Neglia J, Miller W, Weisdorf D: Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 83:3780, 1994
42. Darrington D, Vose J, Anderson J, Bierman P, Bishop M, Chan W, Morris M, Reed E, Sanger, WG, Tarantolo S, Weisenburger D, Kessinger A, Armitage J: Incidence and characterization of secondary myelodysplastic syndrome following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527, 1994
43. Bhatia S, Ramsay N, Steinbuch M, Dusenbery K, Shapiro R, Weisdorf D, Robison L, Miller J, Neglia J: Malignant neoplasms following bone marrow transplantation. Blood 87:3633, 1996
44. Curtis R, Rowlings P, Deeg H, Shriner D, Socie G, Travis L, Horowitz M, Witherspoon R, Hoover R, Sobocinski K, Fraumeni J, Boice J: Solid cancers after bone marrow transplantation. N Engl J Med 336:894, 1997
45. Fetscher S, Finke J, Engelhardt R, Mertelsmann R, Lange W: Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Ann Hematol 74:73, 1997
46. Oddou S, Vey N, Viens P, Bardou V, Faucher C, Stoppa A, Chabannon C, Camerlo J, Bouabdallah R, Gastaut J, Maraninchi D, Blaise D: Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: A report of six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma 31:187, 1998
47. von Neuhoff N, Dreger P, Suttorp M, Marget M, Kell S, Schmitz N: Comparison of different strategies of molecular genetic monitoring following autologous stem cell transplantation in patients with follicular lymphoma. Bone Marrow Transplant 22:161, 1998
48. Andre M, Henry-Amar M, Biaise D, Colombat P, Fleury J, Milpied N, Cahn J, Pico J, Bastion Y, Kuentz M, Nedellec G, Attal M, Ferme C, Gisselbrecht C: Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92:1933, 1998
49. Kaminski M, Zasadny K, Francis I, Milik A, Ross C, Moon S, Crawford S, Burgess J, Petry N, Butchko G, Glenn S, Wahl R: Radiommunotherapy of B-cell lymphoma with Anti-B1 (Anti-CD20) antibody. N Engl J Med 329:459, 1993
50. Press O, Eary J, Appelbaum F, Martin P, Badger C, Nelp W, Glenn S, Butchko G, Fisher D, Porter B, Matthews D, Fisher L, Bernstein I: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329:1219, 1993
51. Press O, Eary J, Applebaum F, Martin P, Nelp W, Glenn S, Fisher D, Porter B, Matthews D, Gooley T, Bernstein I: Phase II trial of 131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336, 1995
52. Kaminski M, Zasadny K, Francis I, Fenner M, Ross C, Milik A, Estes J, Tuck M, Regan D, Fisher S, Glenn S, Wahl R: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14:1974, 1996
53. Liu S, Eary J, Petersdorf S, Martin P, Maloney D, Appelbaum F, Mattews D, Bush S, Durack L, Fisher D, Gooley T, Bernstein I, Press O: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270, 1998
54. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum L, Momin F, Cummings G, Sensenbrenner L: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050, 1994
55. Van Besien K, Khouri I, Giralt S, McCarthy P, Mehra R, Andersson B, Przepiorka D, Gajewski J, Bellare N, Nath R, Romaguera J, McLaughlin P, Korbling M, Deisseroth A, Cabanillas F, Champlin R: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 13:1096, 1995
56. Van Besien K, de Lima M, Giralt S, Moore D, Khouri I, Rondon G, Mehra R, Andersson B, Dyer C, Cleary K, Gajewski J, Champlin R: Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 19:977, 1997
57. Jones R, Ambinder R, Piantadosi S, Santos G: Evidence for a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991
58. Soiffer R, Freedman A, Neuberg D, Fisher D, Alyea E, Gribben J, Schlossman R, Bartlett-Pandite L, Kuhlman C, Murray C, Freeman A, Mauch P, Anderson K, Nadler L, Ritz J: CD6+ T-cell depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant 21:1177, 1998
59. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski W, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D: T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: Clinical and molecular follow-up. Bone Marrow Transplant 21:893, 1998
60. Khouri I, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R: Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817, 1998